You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

CLINICAL TRIALS PROFILE FOR BELUMOSUDIL MESYLATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for belumosudil mesylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT06105554 ↗ Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma Recruiting Sanofi US Services, Inc Phase 1/Phase 2 2024-01-30 Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
NCT06105554 ↗ Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma Recruiting M.D. Anderson Cancer Center Phase 1/Phase 2 2024-01-30 Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for belumosudil mesylate

Condition Name

Condition Name for belumosudil mesylate
Intervention Trials
Multiple Myeloma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for belumosudil mesylate
Intervention Trials
Neoplasms, Plasma Cell 1
Multiple Myeloma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for belumosudil mesylate

Trials by Country

Trials by Country for belumosudil mesylate
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for belumosudil mesylate
Location Trials
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for belumosudil mesylate

Clinical Trial Phase

Clinical Trial Phase for belumosudil mesylate
Clinical Trial Phase Trials
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for belumosudil mesylate
Clinical Trial Phase Trials
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for belumosudil mesylate

Sponsor Name

Sponsor Name for belumosudil mesylate
Sponsor Trials
Sanofi US Services, Inc 1
M.D. Anderson Cancer Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for belumosudil mesylate
Sponsor Trials
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.